Skip to content

D&A at other companies

Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$270M+6.1%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$2.62M+2.8%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$534.67K+31.9%
Globus Medical logo
Globus MedicalGMED
$69.86M+6.4%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2B+13.1%

Other financials

Income statement

See full
Revenue$68.4M+30.1%
Gross profit$49.3M+35.8%
Operating income-$8.1M+37.0%
Net income-$6.3M+44.0%
EPS (diluted)-$0.12+47.8%

Balance sheet

See full
Cash & equivalents$109.3M+37.1%
Total debt$95.0M-4.6%
Total equity$356.2M+20.6%
Total assets$485.6M+14.4%

Cash flow

See full
Operating cash flow$16.4M+148%
CapEx$1.3M-91.2%
Free cash flow$15.1M+299%

Valuation

See full
Market cap$2.13B-26.8%

Profitability

See full
Gross margin74.8%+2.3pp
Operating margin5.4%+4.6pp
Net margin7.3%+6.1pp
FCF margin16.3%

Returns & leverage

See full
Return on equity6.6%+5.5pp
Debt / equity0.3×-0.1×
Current ratio5.2×+0.2×

Where this comes from

Reported directly by Vericel in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Vericel’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vericel's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vericel's D&A?
Vericel (VCEL) reported D&A of $3.27M in Q1 2026.
How has Vericel's D&A changed year-over-year?
Vericel's D&A increased by 21.6% year-over-year, from $2.69M to $3.27M.
What is the long-term trend for Vericel's D&A?
Over 4 years (2021 to 2025), Vericel's D&A has grown at a 40.2% compound annual growth rate (CAGR), from $2.99M to $11.54M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.